Published November 15, 2025 | Version v1
Journal article Open

Coronary artery bypass grafting and percutaneous coronary intervention in coronary artery disease: evidence and guidance

Authors/Creators

  • 1. Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México.
  • 2. Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México

Description

Coronary artery disease (CAD) remains a leading cause of acute myocardial infarction, heart failure, and premature mortality despite advances in prevention and pharmacologic therapy. Revascularization is fundamental for subjects with anatomically significant CAD, particularly those with refractory symptoms or a high risk of adverse outcomes, and it relies on two principal strategies: coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). Within this context, this narrative review aims to clarify how current scientific evidence and the most recent clinical practice guidelines inform the choice between these therapeutic options in clinical settings. To that end, the review examines the pathophysiologic foundations of CAD, its major risk factors, and the indications for revascularization. It then synthesizes key comparative considerations between CABG and PCI, including prevention of cardiovascular events, recovery trajectories, and the likelihood of achieving complete revascularization. Clinical modifiers that influence decision making are analyzed, such as diabetes, patient age, and the anatomical complexity of coronary lesions. In addition, the review outlines technological advances that characterize modern PCI and summarizes fundamental principles for graft selection in CABG. The overall goal is to provide a practical reference framework, centered on multidisciplinary teamwork and shared decision making, that enables optimization of the revascularization strategy in alignment with individual clinical objectives and patient preferences.

Files

3 r Coronary artery bypass grafting and percutaneous.pdf

Files (306.2 kB)

Additional details

References

  • Dehmer GJ, Grines CL, Bakaeen FG, Beasley DL, Beckie TM, Boyd J, et al. 2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization. Journal of the American College of Cardiology. 2023;82(11):1131–74.
  • Duggan JP, Peters AS, Trachiotis GD, Antevil JL. Epidemiology of Coronary Artery Disease. Surg Clin North Am. 2022;102(3):499–516.
  • Zaman S, Wasfy JH, Kapil V, Ziaeian B, Parsonage WA, Sriswasdi S, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025;405(10486):1264–312.
  • Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18–114.
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415–537.
  • Cortese B, Malakouti S, Mazhar W, Leontin Lazar F, Munjal A, Ketchanji Mougang Y. Long-term benefits of drug-coated balloons for coronary artery revascularization. Minerva Cardiol Angiol. 2024;72(5):506–16.
  • Lee J, Park DW, Park SJ. Left Main Disease. Interv Cardiol Clin. 2022;11(4):359–71. 8. Ali ZA, Horst J, Gaba P, Shaw LJ, Bangalore S, Hochman JS, et al. Standardizing the Definition and Analysis Methodology for Complete Coronary Artery Revascularization. J Am Heart Assoc. 2021;10(9):e020110.
  • Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary Artery Bypass Graft Surgery vs Percutaneous Interventions in Coronary Revascularization: A Systematic Review. JAMA. 2013;310(19):2086.
  • Młynarska E, Czarnik W, Fularski P, Hajdys J, Majchrowicz G, Stabrawa M, et al. From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion. Int J Mol Sci. 2024;25(13):7295.
  • Heusch G. Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what? Am J Physiol Heart Circ Physiol. 2019;316(6):H1439–46.
  • Severino P, D'Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci. 2020;21(21):8118.
  • Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular Dysfunction. Circ J. 2022;86(9):1319–28.
  • Jensen RV, Hjortbak MV, Bøtker HE. Ischemic Heart Disease: An Update. Semin Nucl Med. 2020;50(3):195–207.
  • Writing Committee Members, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21–129.
  • Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. JACC. 2023;82(9):833–955.
  • Alexander JH, Smith PK. Coronary-Artery Bypass Grafting. New England Journal of Medicine. 2016;374(20):1954–64.
  • Bakaeen FG, Gaudino M, Whitman G, Doenst T, Ruel M, Taggart DP, et al. 2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. J Thorac Cardiovasc Surg. 2021;162(3):829-850.e1.
  • Beerkens FJ, Claessen BE, Mahan M, Gaudino MFL, Tam DY, Henriques JPS, et al. Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nat Rev Cardiol. 2022;19(3):195–208.
  • Taggart DP, Benedetto U, Gerry S, Altman DG, Gray AM, Lees B, et al. Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years. N Engl J Med. 2019;380(5):437–46.
  • Kusu-Orkar TE, Kermali M, Oguamanam N, Bithas C, Harky A. Coronary artery bypass grafting: Factors affecting outcomes. J Card Surg. 2020;35(12):3503–11.
  • Head SJ, Milojevic M, Taggart DP, Puskas JD. Current Practice of State-of-the-Art Surgical Coronary Revascularization. Circulation. 2017;136(14):1331–45.
  • Phothikun A, Nawarawong W, Tantraworasin A, Phinyo P, Tepsuwan T. The outcomes of three different techniques of coronary artery bypass grafting: On-pump arrested heart, on-pump beating heart, and off-pump. PLoS One. 2023;18(5):e0286510.
  • Shaefi S, Mittel A, Loberman D, Ramakrishna H. Off-Pump Versus On-Pump Coronary Artery Bypass Grafting-A Systematic Review and Analysis of Clinical Outcomes. J Cardiothorac Vasc Anesth. 2019;33(1):232–44.
  • Stefanini GG, Byrne RA, Windecker S, Kastrati A. State of the art: coronary artery stents - past, present and future. EuroIntervention. 2017;13(6):706–16.
  • Brami P, Fischer Q, Pham V, Seret G, Varenne O, Picard F. Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents. J Clin Med. 2023;12(21):6711.
  • Nicolas J, Pivato CA, Chiarito M, Beerkens F, Cao D, Mehran R. Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovasc Res. 2023;119(3):631–46.
  • Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, et al. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025;405(10488):1481–90.
  • Stefanini GG, Holmes DR. Drug-Eluting Coronary-Artery Stents. N Engl J Med. 2013;368(3):254–65.
  • Zimmermann FM, Ding VY, Pijls NHJ, Piroth Z, van Straten AHM, Szekely L, et al. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial. Circulation. 2023;148(12):950–8.
  • Kirov H, Caldonazo T, Rahouma M, Robinson NB, Demetres M, Serruys PW, et al. A systematic review and meta-analysis of percutaneous coronary intervention compared to coronary artery bypass grafting in non-ST-elevation acute coronary syndrome. Sci Rep. 2022;12(1):5138.
  • Sabatine MS, Bergmark BA, Murphy SA, O'Gara PT, Smith PK, Serruys PW, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398(10318):2247–57.
  • Holm NR, Mäkikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191–9.
  • Page E, Kostantinis S, Karacsonyi J, Allana SS, Walser-Kuntz E, Rangan BV, et al. Incidence, treatment and outcomes of coronary artery dissection during percutaneous coronary intervention. J Invasive Cardiol. 2023;35(7):E341–54.
  • Ipek G, Keskin M, Aldag M, Borklu EB, Inan D, Yilmaz H, et al. Balloon Angioplasty Versus Stenting in Patients With ST-Elevated Myocardial Infarction Before Subsequent Coronary Artery By-Pass Grafting. Angiology. 2021;72(9):836–41.
  • Robich MP, Leavitt BJ, Ryan TJ, Westbrook BM, Malenka DJ, Gelb DJ, et al. Comparative effectiveness of revascularization strategies for early coronary artery disease: A multicenter analysis. J Thorac Cardiovasc Surg. 2022;163(2):645-656.e2.
  • Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2021;42(27):2657–64.
  • Niehe SR, Vos NS, Van Der Schaaf RJ, Amoroso G, Herrman JPR, Patterson MS, et al. Two-Year Clinical Outcomes of the REVELATION Study: Sustained Safety and Feasibility of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction. J Invasive Cardiol. 2022;34(1):E39–42.
  • Vlieger S, Cheng JM, Oemrawsingh RM, Weevers APJD, Polad J, Gho B, et al. Clinical Performance of a Paclitaxel Drug-Coated Balloon in Real-World Percutaneous Coronary Intervention Practice: The PEARL Registry. J Invasive Cardiol. 2022;34(6):E462–8.
  • Kitani S, Igarashi Y, Tsuchikane E, Nakamura S, Koshida R, Habara M, et al. Long-Term Clinical Outcomes of Drug-Coated Balloon Following Directional Coronary Atherectomy for Bifurcated or Ostial Lesions in the DCA/DCB Registry. Catheter Cardiovasc Interv. 2025;105(2):273–9.
  • Chen H, Xu J, Chen D, Gao F, Liu Y, Cui H, et al. Randomized study assessing the effectiveness and safety of a novel scoring balloon for percutaneous coronary intervention: the Wedge NC trial. J Thorac Dis. 2025;17(4):2101–12.
  • Niu J, Wang K, Wang W, Liu Y, Yang J, Sun Y, et al. Drug-Coated Balloons versus Drug-Eluting Stents for the Treatment of De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2024;25(12):446.
  • Camaj A, Leone PP, Colombo A, Vinayak M, Stone GW, Mehran R, et al. Drug-Coated Balloons for the Treatment of Coronary Artery Disease: A Review. JAMA Cardiol. 2025;10(2):189–98.
  • Chioncel V, Gherasie F, Iancu A, Avram AG. Coronary Angioplasty with Drug-Coated Balloons: Pharmacological Foundations, Clinical Efficacy, and Future Directions. Medicina (Kaunas). 2025;61(8):1470.
  • Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771–862.